Polynucleotides and polypeptide sequences involved in cancer

Abstract

The present invention relates to polynucleotide and polypeptide sequences which are differentially expressed in cancer cells compared to normal cells. The present invention more particularly relates to the use of these sequences in the diagnosis, prognosis or treatment of cancer and in the detection of cancer cells.

1 - 152 . (canceled) 
     
     
         153 . An antibody or antigen binding fragment capable of binding to a polypeptide having at least 80% sequence identity with SEQ ID NO.:70 and capable of impairing an activity of the polypeptide in ovarian cancer cells. 
     
     
         154 . The antibody or antigen binding fragment of  claim 153 , wherein the polypeptide has a sequence identical to SEQ ID NO.:70. 
     
     
         155 . The antibody or antigen binding fragment of  claim 153 , wherein the activity is ovarian cancer tumorigenesis. 
     
     
         156 . The antibody or antigen binding fragment of  claim 153 , wherein the antibody is a polyclonal antibody. 
     
     
         157 . The antibody or antigen binding fragment of  claim 153 , wherein the antibody is a monoclonal antibody. 
     
     
         158 . The antibody or antigen binding fragment of  claim 153 , wherein the antibody is a chimeric antibody. 
     
     
         159 . The antibody or antigen binding fragment of  claim 153 , wherein the antibody is a humanized antibody. 
     
     
         160 . The antibody or antigen binding fragment of  claim 153 , wherein the antibody is a human antibody. 
     
     
         161 . The antibody or antigen binding fragment of  claim 153 , wherein the antigen binding fragment is a FV, a Fab, a Fab′ or a (Fab′) 2 . 
     
     
         162 . The antibody or antigen binding fragment of  claim 153 , wherein said antibody has sub-nanomolar affinity for the polypeptide. 
     
     
         163 . A pharmaceutical composition comprising:
 a. an antibody or antigen binding fragment capable of binding to a polypeptide having at least 80% sequence identity with SEQ ID NO.:70 and capable of impairing an activity of the polypeptide in ovarian cancer cells and;   b. a pharmaceutically acceptable carrier.   
     
     
         164 . The pharmaceutical composition of  claim 163 , wherein the polypeptide has a sequence identical to SEQ ID NO.:70. 
     
     
         165 . The pharmaceutical composition of  claim 163 , wherein the activity is ovarian cancer tumorigenesis. 
     
     
         166 . The pharmaceutical composition of  claim 163 , wherein the antibody is a polyclonal antibody. 
     
     
         167 . The pharmaceutical composition of  claim 163 , wherein the antibody is a monoclonal antibody or an antigen binding fragment thereof. 
     
     
         168 . The pharmaceutical composition of  claim 163 , wherein the antibody is a chimeric antibody. 
     
     
         169 . The pharmaceutical composition of  claim 163 , wherein the antibody is a humanized antibody. 
     
     
         170 . The pharmaceutical composition of  claim 163 , wherein the antibody is a human antibody. 
     
     
         171 . The pharmaceutical composition of  claim 163 , wherein the antigen binding fragment is a FV, a Fab, a Fab′ or a (Fab′) 2 . 
     
     
         172 . The pharmaceutical composition of  claim 163 , wherein the antibody has sub-nanomolar affinity for the polypeptide.